clinical

The radioprotective effect of oral nanocurcumin in thyroid cancer patients after high dose radioactive iodine administration by examining the amount of inflamatory factor TNFa by ELISA test in patients blood serum

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220212054005N1

Enrollment

Registered

2023-02-18

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer. Malignant neoplasm of parathyroid gland

Interventions

Intervention group: Considering that our goal is to be able to use the results of the study to improve the harmful effects caused by radiation in the treatment of patients, therefore, the nanomicelle

Eligibility

Sex/Gender

All

Age

24 Years to 79 Years

Inclusion criteria

Inclusion criteria: patient informed satisfaction dose received by patients should be between 150 to 200 mci patients should be 24 to 79 years old

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
TNF factor. Timepoint: evaluate the inflammatory factor ,blood samples are taken and evaluated once before the radiopharmaceutical and once a week after the treatment. Method of measurement: Eliza reader.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactseyed Mohammad javad mortazavi

Shiraz University of Medical Sciences

mortazavismj@gmail.com+98 71 3230 3544

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026